Project Grant R43AI197708
Award Date 8/12/26
Completion Date 7/31/27
Dollars Obligated $267K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72211, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $822,280 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on intragraft alloreactive T cells in human solid organ transplantation, with the goal of controlling rejection after transplantation. The research dissects intragraft T cell alloimmunity using longitudinal surveillance biopsies from intestinal...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $750,787 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate central memory stem-cell-like follicular helper T cells (CTFH) and their contribution to durable donor-specific anti-HLA antibodies (DSA) and chronic antibody-mediated rejection (ABMR) in kidney transplant recipients. The research addresses mechanisms of chronic rejection in solid organ...
- The National Institute of Allergy and Infectious Diseases awarded New York University $230,340 on September 30, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antibody-based therapies that block pathogenic donor-specific antibody (DSA) responses in transplant rejection. The three-year training plan, performed at New York University School of Medicine in New York, New York, aims to engineer recombinant antibodies from pathogenic DSAs into blocking...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $251,324 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered organ transplants resistant to antibody-mediated rejection through synthetic biology platforms. The research focuses on designing signal-inducible, drug-controllable endopeptidases for localized antibody degradation within transplanted tissue. The award funds...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $847,299 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunomodulatory mechanisms in allograft rejection. The project, titled "Regulation of Alloimmunity by Intragraft Endothelial Cells," examines how graft microvascular endothelial cells suppress alloimmune responses during transplant rejection. The research will characterize...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arizona $155,479 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to generate transgenic mouse models that overcome immunological barriers to transplantation. The recipient will develop Cre-inducible transgenic mice expressing three distinct immune-evasion modules: genes that suppress complement deposition and membrane attack complex formation; single-chain peptide-B2M-MHC...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $162,792 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI202489) to develop and validate an antibody-mediated rejection (AMR)-on-a-chip platform that recapitulates key pathological features of AMR in kidney transplant rejection in vitro. The recipient will engineer a glomerulus-on-a-chip model using human induced pluripotent stem cell-derived renal...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $184,000 on April 1, 2026, to investigate how CD14 regulates NLRP3 inflammasome signaling pathways in renal tubule epithelial cells during ischemia-reperfusion injury. The work is supported under the Allergy and Infectious Diseases Research program (CFDA 93.855), a project grant assistance type. The research evaluates whether CD14 engages toll-like receptors (TLR2 or TLR4) to trigger NLRP3 signaling in...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $800,097 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop methods for improving antinuclear antibody (ANA) testing and understanding autoimmune disease progression in ANA-positive individuals. The project leverages epidemiological data, biobank resources, and artificial intelligence technologies to address two key knowledge gaps: the long-term risk of autoimmune...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $209,765 on May 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate TIGIT+ B cell therapy as an immunosuppressive strategy to promote transplantation tolerance and suppress acute graft-versus-host disease. The research tests whether TIGIT+ B cells—generated using a novel replication-incompetent recombinant ADV5 vector (ADV5.K7.TIGIT)—can suppress...